38th Annual San Antonio Breast Cancer Symposium. Resumen de las aportaciones más relevantes

Abstract

We summarise the most interesting and clinically relevant works presented at the 38th Annual San Antonio Breast Cancer Symposium (December 2015). In the field of translational research, the main contributions were made in clonal dynamics and tumour heterogeneity, as well as in the possibility of studying emerging resistance mutations with liquid biopsy and next-generation sequencing, as shown by data from the BELLE-2 and BOLERO-2 trials. From the clinical point of view, the final analysis of BCIRG-006 trial and the intermediate analysis of the ExteNET trial will probably change the adjuvant treatment of HER2 breast cancer patients. The results of the ABCSG-18 trial with adjuvant denosumab in luminal breast cancer are consistent with previous data from trials of adjuvant bisphosphonate therapy. In triple-negative breast cancer, interesting data were reported supporting the addition of carboplatin and nab-paclitaxel to neoadjuvant chemotherapy regimens. The CREATE-X trial is the first study showing a survival benefit (larger in triple negative disease) of adjuvant chemotherapy with capecitabine in those patients without pathologic complete response after neoadjuvant chemotherapy. Finally, other problems addressed during the meeting were treatment de-escalation in some patient subgroups, the controversies surrounding and integration of nodal irradiation and axillary surgery, and early clinical results with immune therapy.